Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.

Knight JS, Subramanian V, O'Dell AA, Yalavarthi S, Zhao W, Smith CK, Hodgin JB, Thompson PR, Kaplan MJ.

Ann Rheum Dis. 2015 Dec;74(12):2199-206. doi: 10.1136/annrheumdis-2014-205365. Epub 2014 Aug 7.

2.

Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus.

Knight JS, Zhao W, Luo W, Subramanian V, O'Dell AA, Yalavarthi S, Hodgin JB, Eitzman DT, Thompson PR, Kaplan MJ.

J Clin Invest. 2013 Jul;123(7):2981-93. doi: 10.1172/JCI67390. Epub 2013 Jun 3.

3.

Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice.

Oaks Z, Winans T, Caza T, Fernandez D, Liu Y, Landas SK, Banki K, Perl A.

Arthritis Rheumatol. 2016 Nov;68(11):2728-2739. doi: 10.1002/art.39791.

4.

PDTC attenuate LPS-induced kidney injury in systemic lupus erythematosus-prone MRL/lpr mice.

Zhai JX, Zhang ZX, Feng YJ, Ding SS, Wang XH, Zou LW, Ye DQ.

Mol Biol Rep. 2012 Jun;39(6):6763-71. doi: 10.1007/s11033-012-1501-7. Epub 2012 Feb 9.

PMID:
22318546
5.

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, Abdalrahman Z, Sciumè G, Tsai WL, Trier AM, Nunez L, Mast L, Hoffmann V, Remaley AT, O'Shea JJ, Kaplan MJ, Gadina M.

Arthritis Rheumatol. 2017 Jan;69(1):148-160. doi: 10.1002/art.39818.

6.
7.

Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.

Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.

J Immunol. 2011 Sep 15;187(6):3413-21. doi: 10.4049/jimmunol.1101125. Epub 2011 Aug 17.

8.

Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.

Jiang C, Zhao ML, Scearce RM, Diaz M.

Arthritis Rheum. 2011 Apr;63(4):1086-96. doi: 10.1002/art.30230.

9.

Neutrophil Extracellular Traps Drive Endothelial-to-Mesenchymal Transition.

Pieterse E, Rother N, Garsen M, Hofstra JM, Satchell SC, Hoffmann M, Loeven MA, Knaapen HK, van der Heijden OWH, Berden JHM, Hilbrands LB, van der Vlag J.

Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1371-1379. doi: 10.1161/ATVBAHA.117.309002. Epub 2017 May 11.

PMID:
28495931
10.

Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.

Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B.

J Am Soc Nephrol. 2005 Dec;16(12):3592-601. Epub 2005 Nov 2.

11.

B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus.

Wen J, Doerner J, Chalmers S, Stock A, Wang H, Gullinello M, Shlomchik MJ, Putterman C.

J Neuroinflammation. 2016 Apr 7;13(1):73. doi: 10.1186/s12974-016-0537-3.

12.

Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.

Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.

J Rheumatol. 2010 Jan;37(1):60-70. doi: 10.3899/jrheum.090194. Epub 2009 Dec 1.

PMID:
19955044
13.

Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice.

Nicoletti F, Di Marco R, Zaccone P, Xiang M, Magro G, Grasso S, Morrone S, Santoni A, Shoenfeld Y, Garotta G, Meroni P.

Eur J Immunol. 2000 Feb;30(2):438-47.

14.
15.

Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis.

Knight JS, Luo W, O'Dell AA, Yalavarthi S, Zhao W, Subramanian V, Guo C, Grenn RC, Thompson PR, Eitzman DT, Kaplan MJ.

Circ Res. 2014 Mar 14;114(6):947-56. doi: 10.1161/CIRCRESAHA.114.303312. Epub 2014 Jan 14.

16.

IL-10 regulates murine lupus.

Yin Z, Bahtiyar G, Zhang N, Liu L, Zhu P, Robert ME, McNiff J, Madaio MP, Craft J.

J Immunol. 2002 Aug 15;169(4):2148-55.

17.

Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2.

Yasuda K, Watkins AA, Kochar GS, Wilson GE, Laskow B, Richez C, Bonegio RG, Rifkin IR.

PLoS One. 2014 Jul 30;9(7):e103478. doi: 10.1371/journal.pone.0103478. eCollection 2014.

18.

At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases.

Barnado A, Crofford LJ, Oates JC.

J Leukoc Biol. 2016 Feb;99(2):265-78. doi: 10.1189/jlb.5BT0615-234R. Epub 2015 Dec 11. Review.

19.

Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.

Choi JY, Gao W, Odegard J, Shiah HS, Kashgarian M, McNiff JM, Baker DC, Cheng YC, Craft J.

Arthritis Rheum. 2006 Oct;54(10):3277-83.

20.

Siglec-G deficiency leads to more severe collagen-induced arthritis and earlier onset of lupus-like symptoms in MRL/lpr mice.

Bökers S, Urbat A, Daniel C, Amann K, Smith KG, Espéli M, Nitschke L.

J Immunol. 2014 Apr 1;192(7):2994-3002. doi: 10.4049/jimmunol.1303367. Epub 2014 Mar 5.

Supplemental Content

Support Center